SLU-PP-332 is a groundbreaking estrogen-related receptor (ERR) agonist that represents a major advancement in exercise mimetic research. This research-grade compound is the first ERRα agonist developed for in vivo applications, with exceptional bioavailability and an acceptable safety profile. As a pan-ERR agonist with primary activity at ERRα and ERRγ receptors, SLU-PP-332 directly impacts mitochondrial function, making it a revolutionary tool for studying cellular respiration, exercise mimetics, and anti-aging pathways.

Research Applications & Scientific Mechanisms:

🏃 Exercise Mimetic Research:

• First viable "exercise in a bottle" compound targeting cellular respiration

• 70% increase in endurance capacity and 45% improvement in distance performance

• Enhances mitochondrial density and efficiency without exercise intervention

• 12% body weight reduction in 30-day studies without dietary changes

• Research applications in metabolic syndrome and exercise physiology

⚡ Mitochondrial Function & Cellular Energy:

• Direct mitochondrial health improvement and energy generation enhancement

• Increases mitochondrial density per cell through ERRγ activation

• Reduces oxidative stress and free radical production

• Enhanced oxygen and nutrient utilization at cellular level

• Research applications in cellular aging and energy metabolism disorders

❤️ Cardiovascular Research:

• Improved cardiac ejection fraction in heart failure models

• Significant reduction in cardiac fibrosis and scar tissue formation

• Enhanced fatty acid oxidation and cardiac energy homeostasis

• Increased blood vessel density in skeletal muscle

• Research applications in heart failure, cardiovascular disease, and cardiac protection

🧠 Neurological & Parkinson's Research:

• Targets mitochondrial dysfunction in dopaminergic neurons

• Addresses oxidative stress vulnerability in substantia nigra

• Regulates genes for mitochondrial respiration, autophagy, and synaptic function

• Research applications in Parkinson's disease, Lewy body dementia, and neurodegeneration

• Potential therapeutic pathway for neurodegenerative disorders

🧬 Anti-Aging & Longevity Research:

• Mimics caloric restriction benefits without dietary intervention

• Protects against age-related mitochondrial dysfunction

• Reduces inflammatory cytokines and albumin in urine

• ERR signaling preservation associated with longevity

• Research applications in cellular senescence, aging, and healthspan extension

🫀 Organ Protection Research:

• Kidney function preservation and protection from aging effects

• Autophagy regulation through transcription factor EB (TFEB)

• Prevents accumulation of damaged cells and promotes healthy cell replacement

• Research applications in organ preservation and regenerative medicine

🔬 Unique Research Advantages:

• First ERRα agonist with in vivo bioavailability

• Pan-ERR activity (α, γ primary; β secondary)

• Superior bioavailability compared to previous ERR compounds

• Acceptable safety profile for extended research applications

• Pioneering compound in exercise mimetic field

Published Research Evidence:

• 70% endurance increase and 45% distance improvement in normal-weight mice

• 12% body weight reduction without exercise or dietary changes

• Significant cardiac function improvement in heart failure models

• Mitochondrial density increases and enhanced cellular energy production

• Anti-aging effects equivalent to caloric restriction protocols